Juniper
Corporate brand
UnclaimedJuniper is Eucalyptus Health's international telehealth brand for clinician-led weight-management and menopause-related care.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Juniper is an online healthcare brand operated by Australian telehealth company Eucalyptus Health. It provides digitally delivered weight-management services and menopause-related care through an online platform, with operations reported in Australia, the United Kingdom, Germany, Japan and Canada. The brand is not a conventional consumer-product company: its principal offering is a healthcare pathway that combines online intake, clinical review, consultation, lifestyle support and, where clinically appropriate and legally permitted, prescription treatment. Customers generally begin with an online health assessment or intake process. A clinician then reviews the information and conducts a consultation, with the exact process varying by market and applicable professional rules. Eligible patients may receive prescriptions for regulator-approved treatments used in weight management, including liraglutide, semaglutide and tirzepatide products. Examples include Saxenda, Wegovy, Ozempic, Mounjaro and, in some markets, Zepbound. Medicines are supplied through partner pharmacies rather than functioning as ordinary over-the-counter products. In Australia, advertising restrictions mean that Juniper does not publicly name prescription medicines before a clinical consultation in the same way that consumer brands advertise ordinary products. Juniper became one of Eucalyptus Health's primary brands as the parent company shifted more strongly toward obesity, metabolic health and other digitally delivered medical services in the early 2020s. Its expansion coincided with increasing global demand for GLP-1 receptor agonist medicines and with the growth of private telehealth access to weight-management treatment. Eucalyptus's wider portfolio also includes Pilot, Kin, Software and Compound, giving the group several condition- or audience-focused healthcare brands. The brand's model is vertically integrated relative to a traditional referral pathway: the online platform supports intake, clinical consultation, prescribing workflows, health coaching and medicine fulfilment through pharmacy partners. This structure can make treatment more convenient and scalable, but it has also produced regulatory and professional scrutiny. Australian and UK authorities and medical organisations have examined whether online questionnaires, asynchronous assessments, promotional language and commercial incentives are compatible with safe prescribing and restrictions on advertising prescription-only medicines. In Australia, Juniper has been discussed in connection with scrutiny of online weight-loss advertising, compounded GLP-1 products and the adequacy of real-time clinical assessment. In the United Kingdom, the brand has operated during periods of semaglutide shortage and has faced questions about advertising practices and whether online consumers can obtain injectable treatments without sufficient clinician interaction. Eucalyptus temporarily paused new UK Juniper memberships during a supply constraint in order to prioritise existing patients, later reopening intake as supply conditions improved. Juniper's growth has also been accompanied by commercial expansion and investor interest in Eucalyptus. Reporting in 2025 described substantial growth in the parent company's weight-loss activities and preliminary discussions about a large private funding round, although Juniper itself is not separately listed. The brand has additionally explored technology-assisted care: Eucalyptus announced work with the AI healthcare platform Amigo, while Juniper introduced an AI assistant called June for guidance on nutrition, medication use and weight-loss plateaus. These tools are positioned as support for, rather than replacements for, clinician-led care, but mental-health and medical commentators have stressed the need for safeguards for people vulnerable to eating disorders or other complications. Juniper is therefore best understood as a branded digital healthcare service operating at the intersection of telemedicine, obesity care, prescription-pharmacy distribution and consumer health marketing. Its current positioning combines convenience, structured clinical support and access to medical weight-management options, while its long-term development depends on regulatory compliance, medicine supply, clinical governance and public trust.
History
Juniper emerged as one of the principal consumer-facing brands in Eucalyptus Health's expansion from general telehealth into obesity, metabolic health and related care during the early 2020s. The brand was built around a digital pathway in which prospective patients complete an online intake, receive clinical review and consultation, and may then receive treatment, coaching and pharmacy fulfilment where they meet local clinical and legal requirements. Its growth coincided with increasing demand for GLP-1 receptor agonists used in diabetes and weight management. Juniper's service could involve medicines such as liraglutide, semaglutide or tirzepatide, depending on the market, regulatory status and individual clinical assessment. The brand's operating model connected online patient acquisition with clinician prescribing and partner-pharmacy supply, allowing Eucalyptus to scale across national markets while retaining a recognisable condition-focused brand. In 2023, the Australian operations of Jenny Craig entered voluntary administration. Eucalyptus acquired assets including online infrastructure, broadening the resources available to its portfolio of digital healthcare brands. Juniper continued to expand internationally, operating in Australia, the United Kingdom, Germany, Japan and Canada. The United Kingdom became particularly important to Eucalyptus, although medicine shortages, notably involving Ozempic and semaglutide, led the company to temporarily pause new UK Juniper memberships so existing patients could be prioritised. The service attracted regulatory scrutiny as online weight management became more commercially significant. In Australia, medical organisations and regulators questioned models based mainly on questionnaires or asynchronous review, especially where injectable prescription medicines were involved. The TGA examined whether Juniper communications and advertising could indirectly promote prescription-only medicines. Authorities also investigated the broader use of compounded GLP-1 products, which do not necessarily have the same approval, quality controls and adverse-event reporting arrangements as commercially approved medicines. Australia subsequently prohibited pharmacy compounding of GLP-1 medicines, requiring providers to move patients toward approved products. The United Kingdom generated separate concerns. The Advertising Standards Authority issued advice relating to advertising that could imply NHS-worker endorsement, while wider investigations considered misleading claims and promotion of prescription-only treatments. Later test purchasing raised questions about whether some online providers could supply injectable treatments following questionnaires without a real-time consultation. These issues placed Juniper within a wider debate over the safety, transparency and equity of private digital prescribing. Eucalyptus responded to clinical-governance concerns in 2024 by appointing former Australian deputy chief medical officer Nick Coatsworth as an adviser. The group also continued investing in international growth and technology. In 2025, Eucalyptus announced an arrangement with Amigo to integrate AI health agents into its services, including a Juniper assistant called June. The assistant was described as supporting nutrition guidance, medication information and weight-loss coaching, while clinical responsibility remained with healthcare professionals. Commercial reporting in 2025 described strong growth in Eucalyptus's weight-loss operations and preliminary discussions about a substantial private financing round. Juniper was part of the business environment that generated investor interest, although it is not a separately listed company and publicly reported group-level figures should not be treated as Juniper standalone financial results. At the same time, advertising campaigns, private access pricing and social-media promotion continued to draw attention from regulators, clinicians and eating-disorder advocates. Juniper's history is consequently defined by the rapid scaling of branded telehealth, the arrival of GLP-1 medicines as a major treatment category, international market expansion, and continuing efforts to reconcile convenience and commercial growth with clinical governance, advertising law, medicine supply and patient safety.
- 2025
AI support introduced for Juniper care
[1]Eucalyptus announced an Amigo partnership and Juniper introduced the June assistant to support patient guidance and health coaching alongside clinicians.
- 2024
Clinical governance adviser appointed
[1]Eucalyptus appointed Nick Coatsworth as a clinical governance adviser during scrutiny of compounded semaglutide prescribing.
- 2023
Eucalyptus acquires Jenny Craig Australia assets
[1]Eucalyptus acquired assets and online infrastructure from the Australian Jenny Craig operation after it entered voluntary administration, supporting the development of its broader digital-health portfolio.
- 2023
TGA investigates Ozempic-related emails
[1]The TGA opened an investigation into whether Juniper emails about Ozempic availability constituted unlawful advertising of a prescription-only medicine.
Products and positioning
A digitally convenient, clinician-led private healthcare service focused on weight management and related health needs, combining assessment, medical treatment where appropriate, lifestyle coaching and pharmacy fulfilment.
Telehealth weight management
Juniper Weight Management
A clinician-led online weight-management program combining digital health assessment, clinical review, consultation and lifestyle support. Patients who meet clinical and legal requirements may be prescribed approved medicines such as liraglutide, semaglutide or tirzepatide, with supply handled through partner pharmacies. Availability, medicine choice and consultation requirements vary by country.
Telehealth menopause care
Juniper Menopause Care
A menopause-related digital healthcare service within Juniper's broader telehealth portfolio. It is designed around online access to clinical assessment and support rather than a conventional packaged consumer product. Specific treatment pathways and availability depend on the patient's circumstances and local regulation.
AI health assistant · 2025
June
An AI-supported assistant associated with Juniper's weight-management clinic. It provides automated guidance on subjects such as nutrition, medication use and weight-loss plateaus, and is intended to complement clinician-led care. Its use raises the importance of safeguards, escalation procedures and appropriate handling of patients with complex mental-health or eating-disorder histories.
Controversies
2025
Advertising and consultation-practice scrutiny
Australian and UK commentary examined Juniper's promotional practices and whether online weight-loss injections could be accessed through questionnaire-based processes without adequate real-time clinical consultation.
2024
Scrutiny of compounded GLP-1 prescribing
Juniper was included in wider scrutiny of telehealth prescribing and pharmacy-compounded GLP-1 products, whose regulatory approval, quality assurance and adverse-event reporting can differ from approved commercial medicines.
2023
Investigation into Ozempic-related communications
The Australian TGA investigated whether Juniper emails discussing Ozempic availability indirectly advertised a prescription-only medicine.
Marketing campaigns
- 2025Black Friday promotional activity
Australia
Juniper was among weight-management providers whose Black Friday promotions were discussed in Australian commentary about the appropriateness of marketing services connected with GLP-1 medicines.
Outcome. The activity contributed to continuing professional and regulatory debate about direct-to-consumer promotion, commercial incentives and risks for people vulnerable to eating disorders.
Brand decisions
2025
Pause new UK memberships during medicine shortagesStrategyBackground
Supply constraints affected medicines used in private weight-management services in the United Kingdom.
Action taken
Eucalyptus temporarily paused new Juniper memberships to prioritise medicine supply for existing patients.
Aftermath
New intake resumed after supply conditions improved.
2025
Introduce AI-supported Juniper assistanceProduct launchBackground
Eucalyptus sought to add automation to patient support, triage and health coaching while retaining clinician-led care.
Action taken
Eucalyptus partnered with Amigo and deployed the June AI assistant for Juniper-related guidance.
Aftermath
The move expanded the brand's digital support layer and prompted calls for safeguards for vulnerable patients.
2024
Strengthen clinical governanceStrategyBackground
Eucalyptus faced scrutiny concerning online prescribing and compounded semaglutide.
Action taken
The company appointed Nick Coatsworth as a clinical governance adviser.
Aftermath
The appointment added senior medical oversight while regulatory debate over digital prescribing continued.
2023
Acquire Jenny Craig Australia assetsM&ABackground
Jenny Craig's Australian operations entered voluntary administration, creating an opportunity to acquire digital infrastructure and related assets.
Action taken
Eucalyptus acquired assets including online infrastructure for use across its healthcare brands.
Aftermath
The acquisition broadened the group's platform resources as Juniper and other brands expanded.
Recent events
- Unconfirmed
Reported
Hims & Hers rebrands Juniper into the Hers brand identity in Australia[2]
As part of the Australian launch, Hims & Hers replaced the legacy Juniper entity—Eucalyptus's established women's health venture operated in Australia since 2021—with the Hers global brand identity, while retaining Australian-licensed physicians and continuity of local clinical oversight for existing subscribers.
- Unconfirmed
Reported
Hims & Hers launches women's health platform Hers in Australia[2]
Hims & Hers Health has officially introduced its women-focused telehealth platform Hers to the Australian healthcare market, transforming the Juniper venture into the fully integrated Hers platform. The transitioned platform introduces expanded diagnostic and treatment categories including perimenopause and menopause support, advanced hair restoration formulations, and comprehensive weight management programs, following the company's $1.15 billion acquisition of Eucalyptus earlier in the year.
- Unconfirmed
Juniper reports fourth-quarter results above analyst expectations[3]
Juniper reported fourth-quarter profit and sales above Wall Street expectations. The report gave adjusted earnings per share of 55 cents and revenue of $1.22 billion.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/juniper · Editorial policy · How profiles are compiled